8-K: Alpha Cognition Secures $4.545 Million in Private Placement

Alpha Cognition Inc. has entered into a securities purchase agreement to issue senior convertible notes and warrants for gross proceeds of $4.545 million.

Summary

• Alpha Cognition Inc. has secured a private placement of senior convertible notes and warrants, raising approximately $4.545 million.
• The company will issue senior convertible notes with an aggregate principal amount of $4,545,000.
• The notes will be convertible into common stock at a price of $0.422 per share.
• Initial warrants will be issued to acquire a number of shares equal to 100% of the shares into which the notes are initially convertible.
• Additional warrants will be issued upon the consummation of a qualified offering, representing 50% of the shares into which the notes are initially convertible.
• The notes will bear interest at a rate of 10% per annum, increasing to 20% upon an event of default.
• The notes mature on September 24, 2026, with potential extensions under certain conditions.
• The company intends to use the proceeds for general corporate purposes and to meet ongoing payment requirements under a promissory note with Neurodyn Life Sciences Inc.

Sentiment

Score: 7

Explanation: The document is generally positive as it secures funding for the company, but there are some negative aspects such as the high interest rate and restrictions on future issuances. The sentiment is therefore moderately positive.

Positives

• The private placement provides Alpha Cognition with $4.545 million in funding.
• The company has secured a new source of capital to support its operations and meet its financial obligations.
• The convertible notes and warrants offer investors potential upside through equity conversion and participation in future offerings.
• The company has secured a participation right for the investors for a period of one year from the closing of the sale of the convertible notes and warrants, pursuant to which the investors will have the right to participate in up to 25% of any subsequent offering of the Company.

Negatives

• The notes bear a high interest rate of 10%, which increases to 20% upon an event of default.
• The company is restricted from issuing other convertible notes or securities that would cause a breach of the current notes or warrants.
• The company is restricted from issuing any securities for 30 days following the closing of the sale of the convertible notes and warrants, subject to certain limited exceptions.
• The company is prohibited from effecting or entering into any variable rate transactions for a period of 90 days after the closing date or until the notes are no longer outstanding.

Risks

• The company's obligation to issue conversion shares and warrant shares is absolute and unconditional, regardless of the dilutive effect on other shareholders.
• The number of conversion shares and warrant shares will increase in certain circumstances, potentially diluting existing shareholders.
• The company is subject to various covenants and restrictions, including limitations on issuing other securities and engaging in certain transactions.
• The company is subject to events of default, which could trigger accelerated repayment or other penalties.
• The company is subject to a participation right for the investors for a period of one year from the closing of the sale of the convertible notes and warrants, pursuant to which the investors will have the right to participate in up to 25% of any subsequent offering of the Company.

Future Outlook

The company intends to use the proceeds for general corporate purposes and to meet ongoing payment requirements under a promissory note with Neurodyn Life Sciences Inc. The company is also obligated to file a registration statement for the resale of the shares issued in this transaction.

Industry Context

This private placement is a common method for small to mid-sized companies to raise capital. The use of convertible notes and warrants is a typical structure for such financings, offering investors potential upside while providing the company with immediate funding.

Comparison to Industry Standards

• The terms of this financing, including the interest rate and conversion price, are within the typical range for private placements of this type.
• The inclusion of warrants is a common incentive for investors in such transactions.
• The requirement to register the shares for resale is a standard provision in private placements to provide liquidity to investors.
• The participation right granted to the investors is a common feature in private placements to allow investors to participate in future offerings.

Stakeholder Impact

• Shareholders may experience dilution due to the potential conversion of the notes and exercise of the warrants.
• Employees may benefit from the company's improved financial position.
• Creditors may be impacted by the company's new debt obligations.
• Customers and suppliers may see no immediate impact from this transaction.

Next Steps

• The company is required to file a registration statement with the SEC for the resale of the shares issued in this transaction.
• The company will need to manage its obligations under the notes and warrants, including interest payments and potential conversions.
• The company will need to comply with the covenants and restrictions outlined in the securities purchase agreement.

Key Dates

Keywords

private placement, convertible notes, warrants, common stock, securities, financing, capital raise, dilution, registration rights, qualified offering